Herein, we present the first case of advanced cervical cancer with MSI-H status that showed a notable response to dual combination immunotherapy with nivolumab and ipilimumab after acquired resistance to pembrolizumab....Circulating tumor DNA assay by next generation sequencing (Guardant Health, Redwood City, CA) revealed PIK3CA E542Q mutation (1.8%, variant allele frequency). FoundationOne...results showed TMB-high (24 Muts/Mb) and MSI-high/dMMR...she started on a dual immunotherapy with nivolumab 3 mg/kg once every 2 weeks and ipilimumab 1 mg/kg once every 6 weeks to possibly overcome immunotherapy resistance. After 6 weeks, the follow-up CT scan demonstrated a deep partial response (RECIST 1.1). The left lung mass decreased in size significantly from 72 mm to a 10-mm-sized cystic lesion (Fig. 1D)....To date, she has good adherence to the dual immunotherapy and reported no other symptoms.